Signal Bureau What’s happening · what the record shows

Msi H Metastatic Colorectal Cancer

A topic on our watch list — we track its coverage across 2 domains, including Gi Journal and Pubmed Targeted.

If Msi H Metastatic Colorectal Cancer is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.

What’s changed

Patterns of Progression and Survival in Patients with dMMR/MSI-H Metastatic Colorectal Cancer Treated with Immunotherapy. · Oncologist · 2026-07-20
Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer - News-Medical · CRC Research (Google News) · 2026-07-30
Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status · Clinical Colorectal Cancer · 2026-07-31
Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors · Clinical Colorectal Cancer · 2026-07-25

Ask the engine about Msi H Metastatic Colorectal Cancer ＋ Track Msi H Metastatic Colorectal Cancer for a daily read

Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 6, 9:25 AM PT